Provectus Biopharma Company Profile (NYSE:PVCT)

Analyst Ratings

Consensus Ratings for Provectus Biopharma (NYSE:PVCT) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Provectus Biopharma (NYSE:PVCT)
No equities research coverage for this company has been tracked by


Earnings History for Provectus Biopharma (NYSE:PVCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/10/2016Q116($0.04)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q415($0.05)$1.08 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.03)$1.08 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)


Earnings Estimates for Provectus Biopharma (NYSE:PVCT)
No earnings estimates for this company have been tracked by


Dividend History for Provectus Biopharma (NYSE:PVCT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Provectus Biopharma (NYSE:PVCT)
No insider trades for this company have been tracked by


Latest Headlines for Provectus Biopharma (NYSE:PVCT)
07/20/16 08:50 AMProvectus Biopharmaceuticals Will Hold Its 2016 Second Quarter Business Update Conference Call on Wednesday, …
07/14/16 09:37 AMProvectus Biopharma establishes Australian Subsidiary
06/07/16 06:08 AMProvectus Biopharmaceuticals Will Present at 2016 BIO International Convention in San Francisco, CA - [at noodls] - Download as PDF Presentation Scheduled for 2:45 pm PDT, Wednesday, June 8, 2016, Theater 2 of Moscone Center BIO International Convention Runs June 6-9, 2016 KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus ...
06/01/16 07:03 AMProvectus Biopharmaceuticals Launches Newly Redesigned Website and Official Facebook Page - [at noodls] - Download as PDF New Channels Reflect Company Advancement and Evolution KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT,, a clinical-stage oncology ...


About Provectus Biopharma

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: PVCT
  • CUSIP:
Key Metrics:
  • Previous Close: $0.31
  • 50 Day Moving Average: $0.3525
  • 200 Day Moving Average: $0.3890
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $65.89M
  • Current Year EPS Consensus Estimate: $-0.1200 EPS
  • Next Year EPS Consensus Estimate: $-0.1400 EPS
Additional Links:
Provectus Biopharma (NYSE:PVCT) Chart for Monday, July, 25, 2016